11:56 AM EDT, 04/21/2026 (MT Newswires) -- Whitehawk Therapeutics ( WHWK ) presented "solid" preclinical datasets for its early stage antibody drug conjugates, or ADCs, indicating "substantial clinical evidence" of their potential efficacy against solid tumor targets, Oppenheimer said in a Monday note.

Out of the company's portfolio of ADCs, HWK-007 and HWK-016 are currently under clinical studies and HWK-206 is expected to follow in Q3, the note said.

HWK-007, which targets Protein Tyrosine Kinase 7 or PTK7, demonstrated "potent activity," while HWK-016 showed "clear superiority" to an earlier ADC targeting Mucin 16 or MUC16, Oppenheimer said. HWK-206 also showed enhanced properties against Seizure-Related Homolog Protein 6 or SEZ6, the firm added.

Oppenheimer has an outperform rating and $5 price target on Whitehawk Therapeutics ( WHWK ).

Price: 4.21, Change: -0.02, Percent Change: -0.47